Results for:(32 found)
Jan 2, 2013 12:07PM on Top StocksBy TheStreet Staff

TheStreet's Adam Feuerstein gazes into his crystal ball to offer his biotechnology forecast for the new year.

Dec 27, 2012 11:51AM on Top StocksBy Minyanville.com

Biogen Idec, Pfizer, Bristol-Myers and Celgene are among companies awaiting US approval of key treatments.

Dec 7, 2012 12:31PM on Top StocksBy MSN Money Partner

Roche is upgraded to 'overweight,' while Novartis is downgraded to 'equal weight.'

Nov 2, 2012 9:20AM on Top StocksBy Stock Traders Daily

Right now it may be the main thing that's propping up shares of the gene sequencing company.

Oct 26, 2012 2:33PM on Top StocksBy Minyanville.com

The stock falls after investors get a peek at the royalty-rate structure that pharma giant Roche will pay if a promising new cancer drug is approved.

Oct 2, 2012 11:28AM on Top StocksBy TheStreet Staff

The company's Abraxane delays tumor growth in patients with advanced melanoma.

Sep 17, 2012 11:47AM on Top StocksBy Trefis

The Swiss pharmaceutical has several very strong potential oncology drugs, most of which could be commercially successful.

Tags: RHHBY

VIDEO ON MSN MONEY

DATA PROVIDERS

Copyright © 2014 Microsoft. All rights reserved.

Fundamental company data and historical chart data provided by Morningstar Inc. Real-time index quotes and delayed quotes supplied by Morningstar Inc. Quotes delayed by up to 15 minutes, except where indicated otherwise. Fund summary, fund performance and dividend data provided by Morningstar Inc. Analyst recommendations provided by Zacks Investment Research. StockScouter data provided by Verus Analytics. IPO data provided by Hoover's Inc. Index membership data provided by Morningstar Inc.

MARKET DISPATCHES

No more Dispatches; here's where to find market news

The Market Dispatches column has been discontinued. Here's where to find the latest stock and business news on MSN Money, and the latest from market writer Charley Blaine.

More